Extra data boosts Lundbeck's agitation case
Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.
by albert rønning-andersson, translated by catherine brett
Lundbeck and its partner Otsuka Pharmaceuticals presented positive phase III data at the Clinical Trials for Alzheimer’s Disease (CTAD) conference concerning their candidate Rexulti (brexpiprazol), supporting their bid to get it approved within the agitation indication.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Axsome races for Alzheimer's agitation approval
For subscribers
